IN
INMD.US InMode Ltd
- Market cap
- USD 764M
- P/E
- 11.2x
- P/B
- 1.17x
- ROE
- 9.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INMD.US undervalued?
Graham numberINMD.US trades 23.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InMode Ltd fundamental analysis
No fundamental analysis for InMode Ltd yet.
InMode Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InMode Ltd
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatment…
Full company profileInMode Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InMode Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.1M | 53.5M | 100M | 156M | 206M | 358M | 454M | 492M | 395M | 370M | 360M |
| Gross Profit | 17.4M | 44.4M | 85.1M | 136M | 175M | 304M | 381M | 411M | 317M | 291M | 273M |
| Operating Income | 669K | 8.95M | 23.5M | 59.6M | 72.8M | 167M | 198M | 196M | 113M | 85.4M | 53.1M |
| EBITDA | 820K | 9.15M | 31.7M | 59.9M | 73.3M | 169M | 202M | 218M | 144M | 111M | 59.6M |
| Net Income | 336K | 8.82M | 22.4M | 61.1M | 75.0M | 165M | 162M | 198M | 181M | 93.8M | 63.3M |
| EPS | 0.01 | 0.14 | 0.35 | 0.80 | 0.89 | 1.92 | 1.89 | 2.30 | 2.25 | 1.43 | 1.09 |
| Balance Sheet | |||||||||||
| Total Assets | 16.5M | 39.4M | 81.1M | 218M | 296M | 479M | 644M | 863M | 786M | 766M | 740M |
| Total Liabilities | 7.37M | 20.0M | 36.4M | 38.6M | 40.3M | 62.7M | 89.8M | 75.9M | 81.9M | 83.2M | 89.3M |
| Shareholders' Equity | 8.92M | 19.5M | 43.3M | 176M | 254M | 416M | 555M | 787M | 704M | 683M | 651M |
| Cash & Short-term Investments | 8.28M | 25.0M | 61.3M | 193M | 261M | 416M | 547M | 742M | 596M | 555M | 513M |
| Total Debt | - | - | - | 744K | 1.24M | 4.52M | 4.96M | 9.02M | 7.82M | 13.2M | 3.58M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.00M | 14.6M | 36.9M | 62.2M | 79.2M | 175M | 182M | 177M | 133M | 85.3M | 63.8M |
| Capital Expenditure | 188K | 189K | 381K | 693K | 463K | 939K | 1.58M | 705K | 669K | 972K | 771K |
| Free Cash Flow | 2.81M | 14.4M | 36.5M | 61.5M | 78.8M | 174M | 180M | 176M | 132M | 84.3M | 63.0M |
| Ratios | |||||||||||
| ROE | 3.8% | 45.3% | 51.7% | 34.7% | 29.5% | 39.7% | 29.1% | 25.1% | 25.8% | 13.7% | 9.7% |
| ROA | 2.0% | 22.4% | 27.6% | 28.0% | 25.4% | 34.5% | 25.1% | 22.9% | 23.1% | 12.2% | 8.6% |
| Net Profit Margin | 1.5% | 16.5% | 22.3% | 39.1% | 36.4% | 46.1% | 35.6% | 40.2% | 45.9% | 25.3% | 17.6% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InMode Ltd dividends
InMode Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Oct 1, 2021.
Who owns InMode Ltd
- Insiders 13.22%
- Institutions 56.84%
- Public & others 29.95%
- Shares outstanding 57.5M
- Free float 48.0M
Top funds holding INMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Janus Henderson Small Cap Value L | 966K | 1.68% | 0.00% | Sep 2026 |
| North Growth US Equity | 606K | 1.05% | 0.00% | Mar 2026 |
| iShares Core MSCI EAFE ETF | 557K | 0.97% | 0.00% | Oct 2026 |
| JPMorgan Small Cap Blend A | 409K | 0.71% | +2.75% | Sep 2026 |
| Old Westbury Small & Mid Cap Strategies | 341K | 0.59% | -9.25% | Jul 2026 |
| Hotchkis & Wiley Sm Cp Divers Val I | 193K | 0.34% | 0.00% | Sep 2026 |
| iShares MSCI EAFE Small-Cap ETF | 172K | 0.30% | 0.00% | Oct 2026 |
| IG Mackenzie Global Health Care B | 162K | 0.28% | 0.00% | Aug 2026 |
| iShares Core MSCI Total Intl Stk ETF | 154K | 0.27% | 0.00% | Oct 2026 |
| ARK Israel Innovative Technology ETF | 143K | 0.25% | 0.00% | Oct 2026 |
| Principal SmallCap Value II Instl | 119K | 0.21% | 0.00% | Sep 2026 |
| BlackRock Global Equity Mkt Netrl Instl | 118K | 0.21% | -23.04% | Aug 2026 |
| iShares MSCI Israel ETF | 102K | 0.18% | 0.00% | Oct 2026 |
| SEI Tax-Managed Small/Mid Cap F (SIMT) | 102K | 0.18% | +17.23% | Oct 2026 |
| iShares Core MSCI Intl Dev Mkts ETF | 99.7K | 0.17% | 0.00% | Oct 2026 |
| Schwab Fundamental International SmEqETF | 99.2K | 0.17% | 0.00% | Oct 2026 |
| Amplify BlueStar Israel Technology ETF | 86.0K | 0.15% | 0.00% | Oct 2026 |
| SEI Select Small Cap ETF | 73.7K | 0.13% | 0.00% | Oct 2026 |
| Mediolanum BB Global Sm Cp Eq LA | 73.6K | 0.13% | 0.00% | Jun 2026 |
| AST Small-Cap Equity Portfolio | 72.6K | 0.13% | 0.00% | Sep 2026 |
Top institutions holding INMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Doma Perpetual Capital Management LLC | 2.73M | 4.75% | -10.97% | Jun 2026 |
| Acadian Asset Management LLC | 2.58M | 4.49% | 0.00% | Sep 2026 |
| BlackRock Inc | 2.50M | 4.34% | +10.67% | Jun 2026 |
| Renaissance Technologies Corp | 2.44M | 4.23% | +1.87% | Sep 2026 |
| MENORA MIVTACHIM HOLDINGS LIMITED | 2.04M | 3.55% | 0.00% | Jun 2026 |
| Steel Partners Holdings LP | 1.83M | 3.18% | +1.86% | Jun 2026 |
| Millennium Management LLC | 1.75M | 3.04% | +50.80% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.12M | 1.94% | -15.76% | Jun 2026 |
| Systematic Financial Management LP | 1.02M | 1.77% | -12.01% | Jun 2026 |
| Jupiter Topco LLC | 966K | 1.68% | 0.00% | Jun 2026 |
| Hotchkis & Wiley Capital Management LLC | 739K | 1.28% | -2.09% | Jun 2026 |
| State Street Corp | 709K | 1.23% | +4.74% | Jun 2026 |
| JPMorgan Chase & Co | 560K | 0.97% | +26.25% | Jun 2026 |
| Citadel Advisors Llc | 493K | 0.86% | +341.00% | Jun 2026 |
| Yelin Lapidot Holdings Management Ltd | 373K | 0.65% | -3.55% | Jun 2026 |
| The Goldman Sachs Group Inc | 372K | 0.65% | -63.18% | Jun 2026 |
| Disciplined Growth Investors Inc | 319K | 0.55% | +19.54% | Jun 2026 |
| Point72 Asset Management, L.P. | 294K | 0.51% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 262K | 0.45% | +16.41% | Jun 2026 |
| O'Shaughnessy Asset Management LLC | 246K | 0.43% | -6.43% | Jun 2026 |
InMode Ltd company profile
- Company name
- InMode Ltd
- Ticker
- INMD.US
- ISIN
- IL0011595993
- Exchange
- USA Stocks
- Listed since
- Aug 8, 2019
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 660
- Fiscal year end
- December
- Address
- Tavor Building, Yokne'am, Israel, 2069206
- Phone
- 972 4 909 6313
- Website
- inmodemd.com
About InMode Ltd
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
InMode Ltd management
8- Dr. Michael Kreindel Ph.D.Co-Founder, CTO & Director · born 1968
- Mr. Alon YaariChief Operations Officer
- Ms. Nava Tal-LaunerChief Information Officer
- Mr. Yair MalcaConsultant · born 1978
- Mr. Michael DennisonPresident of North America · born 1981
- Mr. Moshe MizrahyCo-Founder, CEO & Director · born 1953
- Mr. Moshe ItzkovichChief Financial Officer
- Dr. Eran KriegerChief Medical Officer